All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
brequinar sodium
Known as:
Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate
Â
The sodium salt form of Brequinar. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This…Â
(More)
National Institutes of Health
Topic mentions per year
Topic mentions per year
1988-2016
0
5
10
15
1988
2016
Related topics
Related topics
2 relations
Narrower (1)
DuP 785
brequinar
Related mentions per year
Related mentions per year
1985-2018
1980
1990
2000
2010
2020
brequinar sodium
brequinar
DuP 785
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Wolfgang Knecht
,
J Henseling
,
M. Loeffler
Chemico-biological interactions
2000
Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis…Â
(More)
Is this relevant?
1994
1994
Novel mechanisms of brequinar sodium immunosuppression on T cell activation.
Todd Forrest
,
Russell E Ware
,
Timothy D. Howard
,
Bruce D. Jaffee
,
Scott Denning
Transplantation
1994
Brequinar sodium (BQR) is a novel immunosuppressive agent that acts by inhibiting the activity of dihydroorotate dehydrogenase…Â
(More)
Is this relevant?
1993
1993
Multicenter phase II study of brequinar sodium in patients with advanced breast cancer.
Rachel Cody
,
D. Stewart
,
+4 authors
John W. Gyves
American journal of clinical oncology
1993
In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were…Â
(More)
Is this relevant?
1992
1992
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
S. F. Chen
,
Frank W. Perrella
,
Deanna Behrens
,
Lauren M. Papp
Cancer research
1992
The novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4…Â
(More)
Is this relevant?
1992
1992
The prolongation of concordant hamster-to-rat cardiac xenografts by brequinar sodium.
Duncan Cramer
,
Fiona Chapman
,
+5 authors
Leonard Makowka
Transplantation
1992
Brequinar sodium (BQR) prevents cell proliferation by virtue of its inhibition of de novo pyrimidine biosynthesis. The…Â
(More)
Is this relevant?
1992
1992
The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.
Duncan Cramer
,
Fiona Chapman
,
+4 authors
Leonard Makowka
Transplantation
1992
Brequinar sodium (BQR) prevents cell proliferation by virtue of its inhibition of de novo pyrimidine biosynthesis. BQR is capable…Â
(More)
Is this relevant?
1990
1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
D. Noe
,
Erick K Rowinsky
,
+7 authors
Daria Ettinger
Cancer research
1990
Brequinar sodium is a quinoline carboxylic acid derivative that has shown antitumor activity in a number of in vivo murine and…Â
(More)
Is this relevant?
1990
1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
G. J. Peters
,
Gilberto Schwartsmann
,
+4 authors
Henk M W Pinedo
Cancer research
1990
Little is known about the in vivo effects of inhibition of the mitochondrial pyrimidine de novo synthesis enzyme dihydroorotic…Â
(More)
Is this relevant?
1989
1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Carlos Arteaga
,
T. D. Brown
,
+6 authors
Guenter Weiss
Cancer research
1989
Brequinar sodium is a 4-quinolinecarboxylic acid analogue that inhibits dihydroorotate dehydrogenase and subsequent de novo…Â
(More)
Is this relevant?
1989
1989
Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
Gilberto Schwartsmann
,
Ellen Bork
,
+6 authors
Henk M W Pinedo
Cancer
1989
Brequinar sodium (NSC 368390; DUP 785) is a new inhibitor of pyrimidine de novo biosynthesis which has completed Phase I clinical…Â
(More)
Is this relevant?